Abstract library

65 results for "derived peptides".
#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Sergio Pedraza-Arévalo
Authors:
#516 Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors
Introduction: Octreotide derived radiolabelled peptides have been widely used for somatostatin receptor (sstr) imaging. Clinically used radiopeptides exclusively target sstr subtype 2. But radiolabeled Lanreotide has been claimed to bind sstr 2, 3 and 5.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emre Demirci
Authors:
Keywords: Octreotide PET
#2180 BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model
Introduction: NECs of colon origin are orphan and highly aggressive neoplasms with limited molecular knowledge.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jaume Capdevila
Authors:
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors:
#2181 Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth
Introduction: Neuroendocrine tumors (NETs) are a genetically diverse set of rare tumors, which have limited treatment options. The development of more effective therapies for NETs has been limited in part by the absence of in vitro and in vivo models that accurately represent the heterogeneity of these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Talya Dayton
Authors:
#459 Differential Claudin-1 Gene Expression in Neural Crest-Derived Tumors of Common Embryological Origin
Introduction: Pheochromocytoma and paraganglioma are neural crest-derived tumors originating from chromaffin cells, with the former being intra–adrenal in location, while the latter are extra-adrenal.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Miss Beatrice Philip
Authors:
Keywords: Claudin-1
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors:
#1113 A Novel Approach for a Metastatic Gut-Derived Neuroendocrine Tumour: Simultaenous Intestinal and Vascularised Sentinel Forearm Flap Transplantation
Introduction: Non-resectable tumours involving the mesenteric root are an indication for intestinal and multivisceral transplantation (MVT). Vascularised sentinel forearm flaps (VSFF) offer possibilities for monitoring graft rejection and tailoring immunosuppression (IS) regimens.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
Authors:
#1222 The Clinical Utility of Blood Derived Gene Cluster Analysis of Neuroendocrine Tumors Using Neoplasia Hallmark Criteria
Introduction: We developed a multianalyte blood (51 transcript) assay (MAAA) for GEP-NETs with a sensitivity (98%) and specificity (97%).
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors:
Keywords: PCR
#1558 Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Gut-Derived Neuroendocrine Tumour: Follow-up
Introduction: We previously reported the first documented case of a novel approach in a patient with extensive mesenteric metastases from a small bowel (SB) NET: this combined multivisceral transplantation (MVT) and a vascularised sentinel forearm flap (VSFF) from the same donor.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
Authors: